Primatesta P, Poulter N R
Department of Epidemiology and Public Health, Royal Free and University College Medical School, London WC1E 6BT.
BMJ. 2000 Nov 25;321(7272):1322-5. doi: 10.1136/bmj.321.7272.1322.
To evaluate the prevalence of the use of lipid lowering agents and its relation to blood lipid concentrations in English adults.
Cross sectional survey.
England, 1998.
Nationally representative sample of 13 586 adults (aged >/=16 years) living in non-institutional households.
Mean blood concentrations of total cholesterol and high density lipoprotein (HDL) cholesterol, and the ratio of total cholesterol to HDL cholesterol, in participants classified by age and sex; prevalence of raised total cholesterol concentrations and increased ratio of total to HDL cholesterol; prevalence of use of lipid lowering agents and the lipid concentrations of people taking them.
Mean total cholesterol concentrations were 5.47 (SE 0. 02) mmol/l in men and 5.59 (0.02) mmol/l in women. Mean HDL cholesterol concentrations were 1.28 (0.01) mmol/l in men and 1.55 (0.01) mmol/l in women. Overall, of 10 569 adults who had a valid cholesterol measurement taken 7133 (67.5%; 95% confidence interval 66.5% to 68.4%) had a total cholesterol concentration >/=5 mmol/l, 2804 (26.5%; 25.7% to 27.4%) had a ratio of total cholesterol to HDL cholesterol >/=5 mmol/l, and 237 (2.2%; 1.9% to 2.5%) reported taking lipid lowering drugs. Of 117 participants with no history of cardiovascular disease but whose estimated 10 year risk of coronary heart disease was >/=30% and whose total cholesterol concentration was >/=5 mmol/l, four (3%) were taking lipid lowering drugs. Of 385 adults aged 16-75 with a history of coronary heart disease and eligible for lipid lowering treatment, 114 (30%; 25% to 34%) were taking lipid lowering drugs, of whom only 50 (44%; 35% to 53%) had a total cholesterol concentration <5 mmol/l.
Despite the high prevalence of dyslipidaemia in English adults, the proportion of adults taking lipid lowering drugs in 1998 was only 2.2%. Rates of treatment were low among high risk patients eligible for primary prevention with lipid lowering drugs, and less than one third of patients with established cardiovascular disease received such treatment.
评估英国成年人中降脂药物的使用情况及其与血脂浓度的关系。
横断面调查。
英国，1998年。
居住在非机构家庭中的13586名成年人（年龄≥16岁）的全国代表性样本。
按年龄和性别分类的参与者中总胆固醇和高密度脂蛋白（HDL）胆固醇的平均血浓度、总胆固醇与HDL胆固醇的比值；总胆固醇浓度升高和总胆固醇与HDL胆固醇比值升高的患病率；降脂药物的使用情况以及服用者的血脂浓度。
男性总胆固醇平均浓度为5.47（标准误0.02）mmol/L，女性为5.59（0.02）mmol/L。男性HDL胆固醇平均浓度为1.28（0.01）mmol/L，女性为1.55（0.01）mmol/L。总体而言，在10569名进行了有效胆固醇测量的成年人中，7133人（67.5%；95%置信区间66.5%至68.4%）总胆固醇浓度≥5 mmol/L，2804人（26.5%；25.7%至27.4%）总胆固醇与HDL胆固醇的比值≥5 mmol/L，237人（2.2%；1.9%至2.5%）报告正在服用降脂药物。在117名无心血管疾病病史但估计10年冠心病风险≥30%且总胆固醇浓度≥5 mmol/L的参与者中，4人（3%）正在服用降脂药物。在385名年龄在16 - 75岁、有冠心病病史且符合降脂治疗条件的成年人中，114人（30%；25%至34%）正在服用降脂药物，其中只有50人（44%；35%至53%）总胆固醇浓度<5 mmol/L。
尽管英国成年人中血脂异常患病率很高，但1998年服用降脂药物的成年人比例仅为2.2%。在有资格接受降脂药物一级预防的高危患者中，治疗率较低，且不到三分之一的已确诊心血管疾病患者接受了此类治疗。
